Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases

Simple item page

Simple item page

Full item details

creativework.keywords - en
Antibodies, Viral
COVID-19 Vaccines*
COVID-19* / prevention & control
Canada
Humans
SARS-CoV-2
Tumor Necrosis Factor Inhibitors
Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine
dc.contributor.author
Dayam, Roya M.
Law, Jaclyn C.
Goetgebuer, Rogier L.
Chao, Gary Y.C.
Abe, Kento T.
Sutton, Mitchell
Finkelstein, Naomi
Stempak, Joanne M.
Pereira, Daniel
Croitoru, David
Acheampong, Lily
Rizwan, Saima
Rymaszewski, Klaudia
Milgrom, Raquel
Ganatra, Darshini
Batista, Nathalia V.
Girard, Melanie
Lau, Irene
Law, Ryan
Cheung, Michelle W.
Rathod, Bhavisha
Kitaygorodsky, Julia
Samson, Reuben
Hu, Queenie
Hardy, W. Rod
Haroon, Nigil
Inman, Robert D.
Piguet, Vincent
Chandran, Vinod
Silverberg, Mark S.
Gingras, Anne-Claude
Watts, Tania H.
dc.date.accessioned
2024-07-05T19:27:02Z
dc.date.available
2024-07-05T19:27:02Z
dc.date.issued
2022-06-08
dc.description.abstract - en
BACKGROUND: Limited information is available on the impact of immunosuppressants on COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID). METHODS: This observational cohort study examined the immunogenicity of SARS-CoV-2 mRNA vaccines in adult patients with inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, or psoriatic disease, with or without maintenance immunosuppressive therapies. Ab and T cell responses to SARS-CoV-2, including neutralization against SARS-CoV-2 variants, were determined before and after 1 and 2 vaccine doses. RESULTS: We prospectively followed 150 subjects, 26 healthy controls, 9 patients with IMID on no treatment, 44 on anti-TNF, 16 on anti-TNF with methotrexate/azathioprine (MTX/AZA), 10 on anti–IL-23, 28 on anti–IL-12/23, 9 on anti–IL-17, and 8 on MTX/AZA. Ab and T cell responses to SARS-CoV-2 were detected in all participants, increasing from dose 1 to dose 2 and declining 3 months later, with greater attrition in patients with IMID compared with healthy controls. Ab levels and neutralization efficacy against variants of concern were substantially lower in anti-TNF–treated patients than in healthy controls and were undetectable against Omicron by 3 months after dose 2. CONCLUSIONS: Our findings support the need for a third dose of the mRNA vaccine and for continued monitoring of immunity in these patient groups.
dc.description.sponsorship
Funded by a donation from Juan and Stefania Speck and by Canadian Institutes of Health (CIHR)/COVID-Immunity Task Force (CITF) grants VR-1 172711 and VS1-175545 (to THW and ACG), CIHR FDN-143250 (to THW), GA2-177716 (to VC, ACG, and THW), and GA1-177703 (to ACG) and the CIHR rapid response network to SARS-CoV-2 variants, CoVaRR-Net (to ACG).
dc.identifier.doi
https://doi.org/10.1172/jci.insight.159721
dc.identifier.issn
2379-3708
dc.identifier.pubmedID
35471956
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/2663
dc.language.iso
en
dc.publisher
American Society for Clinical Investigation
dc.rights - en
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.rights - fr
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.rights.openaccesslevel - en
Gold
dc.rights.openaccesslevel - fr
Or
dc.rights.uri - en
https://creativecommons.org/licenses/by/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by/4.0/deed.fr
dc.subject - en
Health
dc.subject - fr
Santé
dc.subject.en - en
Health
dc.subject.fr - fr
Santé
dc.title - en
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
dc.type - en
Article
dc.type - fr
Article
local.acceptedmanuscript.articlenum
e159721
local.article.journalissue
11
local.article.journaltitle
JCI Insight
local.article.journalvolume
7
local.pagination
1-14
local.peerreview - en
Yes
local.peerreview - fr
Oui
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: dayam-accelerated-waning-of-immunity-to-sars-cov-2-mrna-vaccines.pdf

Size: 4.9 MB

Format: PDF

Download file

Page details

Date modified: